Breast Cancer

- Locally advanced metastatic TNBC
- Triple negative breast cancer (TNBC)
- TNBC or HR+
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- BRCA Mutant
- Advanced metastatic or recurrent tumors with pathogenic BRCA 1/2 mutated

- 10525: A Phase I/II Trial of ZEN-3694 with Pembrolizumab and Nab Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer
- 1030: A Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
- 10546: Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
- 10146: Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer
- ▼ 10449: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer
- ▼ 10551: Phase I/II Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: January 17, 2024